Nanomedicine is a Hot Sector Expected to Grow by a Factor of Ten Times in the Near to Mid-Term and NanoViricides, Inc. (NYSE-American: NNVC) is a Leader in the Technology
“President and founder Anil R. Diwan, PhD. NNVC holds an exclusive, worldwide license to this technology for its antiviral drugs”
Good day everyone,
One of the newest frontiers in biopharma is nanomedicine. The application of nanotechnology for medical purposes is defined as the use of nanomaterials for diagnosis, monitoring, control, prevention, and treatment of diseases. I’ve been watching a small cap company that is a pioneer and is leading the way in this new and promising landscape.
NanoViricides, Inc. (NYSE-American: NNVC) is a company developing novel nanoviricide drug candidates for the eradication of viruses.
Current price $4.37 (at market close 10-8-21)
I urge to to read the recent corporate presentation to see the full potential here.
NNVC has a small share structure with 11.61M (est.) shares outstanding and 10.38M (est.) in the float. We note the shares are trading 50% off their March high of $8.71/share.
When I look at the company stock chart I note the shares have crossed their 50 DMA and 200 DMA of $4.17 and $4.21 respectively in a bullish manner. Furthermore, the support level for the company shares seems to have been increasing through this year and currently looks like $4.00 could be the latest support level. As the shares are coming off that support level and have crossed their 50 and 200 DMAs a bounce may be coming in the near term.
I wanted to know which other companies might be involved with this nascent sector. First, I found a dozen private start-ups with funding ranging from $20M to $500M. My search for public companies involved in nanomedicine only turned up big pharma companies with valuations in the billions.
NNVC could be your opportunity to buy shares in this rapidly growing sector (MarketWatch projects a 15.1% CAGR) at a low entry level.
NNVC is applying its nano technology to a broad range of viruses including influenza (both for out- patients and hospitalized patients), HIV, Ebola, Dengue/Marburg, Rabies, HSV Lesions, Herpes Keratitis, Hepatitis, Cold Sores, Shingles and Covid 19. Treatment for all these indications (except covid 19) are in pre-clinical studies preparing for an IND submission to the FDA. The company’s covid 19 development program has jumped to the front of the line.
NNVC and covid 19
Covid 19 has made many of us keenly aware of how viruses attack us, and the potential biopharma products used to combat them. The vaccines against covid have been quite effective but they are not a cure-all. Vaccinated people still get infected, just to a lesser degree, and many people could not or would not use the vaccines.
Antivirals have been in the biopharma arsenal for a long time to fight harmful viruses like RSV, Ebola, HIV, coronaviruses, and influenza and lowering the risk of spreading viruses to others. Antivirals work in several different ways to keep viruses out of the human body. Remdesivir, by Gilead Sciences is the only approved antiviral for covid 19, but it has its limitations because it metabolizes quickly inside the body and increasing the dosage can be toxic. NanoViricides created a complementary formulation to increase the effectiveness of remdesivir.
The NNVC product NV-CoV-2-R works by encapsulating remdesivir and preventing it from metabolizing too quickly. So far, the clinical trials show that NV-CoV-2-R extends the effectiveness of remdesivir. NV-CoV-2, the parent nanoviricide drug, works by attacking the virus particle outside cells while remdesivir is attacking the virus reproduction inside cells. By using the encapsulation platform, doctors should also be able to use a higher concentration of remdesivir.
NNVC product candidates are based on TheraCour® technology invented and developed by company president and founder Anil R. Diwan, PhD. NNVC holds an exclusive, worldwide license to this technology for its antiviral drugs. The technology is protected by two broad international patent applications that have resulted in several international patents. These patents cover compositions of matter, processes of manufacture, methods of use, and fields of use. Additional patent applications are anticipated, and the Company intends to patent each drug separately as well.
NNVC has one feature that makes it stand out from most development stage biopharma companies. They have their own manufacturing facility. It’s a multi-kilogram-scale c-GMP capable manufacturing facility for the drug substance as well as drug product, in Shelton, CT. This facility is 100% owned by the Company with no mortgage and is a major asset. This flexible, multi-product pilot plant can supply drug product for all their programs through human clinical trials. Further, it is capable of production for initial marketing, enabling early revenues upon drug approval, of about $100M-$500M per year.
NanoViricides, is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. They are developing clinical candidates for the treatment of COVID-19 disease caused by SARS-CoV-2 coronavirus. Their other lead drug candidate is NV-HHV-101 with its first indication as dermal topical cream for the treatment of shingles rash. In addition, the Company has several antiviral programs in various pre-clinical stages.
Stay tuned for more information about NNVC.
The Traders News Group
Do we disclose any information to outside parties?
What information do we collect?
We collect information from you when you subscribe to our newsletter or fill out a form on one of our social platforms. This includes your email address and or mobile phone number.
When registering on our site, as appropriate, you may be asked to enter your: e-mail address and or mobile number.
What do we use your information for?
When we collect your email or mobile number it is used for one purpose to send you the information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.
Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, other than for the express purpose of delivering the information on small cap stocks that you requested.
We send periodic emails
The email address you provide may be used to send you information, the small acp stock reports you requested, respond to inquiries, and/or other requests or questions.
How do we protect your information?
We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use secure third parties to send email and sms messages to you.
Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act.
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
Please Note: TNS LLC and its employees are not a registered investment advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.